Enteric Coating and Delayed Release: When It Actually Matters

Somewhere on your shelf there is probably a bottle that charges a premium for two words: enteric coated. The promise is intuitive and it sells well. Your stomach is a vat of acid, the pill is precious, so of course you armor it. The trouble is that a coating is not a general-purpose upgrade. It is a specific engineering fix for a specific problem, and when the product does not have that problem, the coating ranges from pointless to genuinely counterproductive.

This is the version a formulator would give a colleague. A coating is worth paying for in two situations: the active ingredient is destroyed by stomach acid, or it needs to do its work somewhere further down. That is the whole list. Everything else is a story attached to a price increase, and in a few cases the coating measurably works against you.

What a coating actually does

An enteric film is a thin polymer shell chosen for one property: it is insoluble in acid and soluble once the pH climbs. A fasted stomach sits down around pH 1.7. The small intestine past the pylorus is far closer to neutral, roughly 6.6 in the upper reaches and about 7.5 by the end of the ileum. Wrap a tablet in a polymer engineered to ionize above a chosen pH and it will hold together in the stomach and let go downstream. That is the entire trick, and it is an elegant one.

The polymers that do this are a short, identifiable list, which turns out to be the single most useful thing a shopper can know. Real coatings use cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate, methacrylic acid copolymer (commonly sold under the Eudragit name), polyvinyl acetate phthalate, or shellac. Each is built to a target pH, and formulators pick along that scale to aim at a region of gut: the common methacrylic grades open above about 5.5, others are set nearer 6.0, and the ones meant for the far end of the small bowel or the colon wait until around 7.0. Shellac sits at the patient end of that range too.

Why the trigger misses more often than you think

Here is what more labels ought to admit. The coating is not set to a timer, it is set to a chemical condition, and it is released into a body that does not hold that condition steady. Three things make a delayed-release product an aim rather than a guarantee.

Your gut does not empty on schedule. When researchers tracked a single swallowed unit through fasted volunteers, gastric emptying ranged from 7 minutes to 202 minutes, with a median of 30. That is a roughly thirty-fold spread between people taking the same product the same way. In the same line of work, tablets that did not leave the stomach with the meal were held through its quiet period and only moved later, when the sweeping contractions resumed. The label says delayed release; it cannot say by how long.

A meal moves the pH the wrong way. This one surprises people. You would assume that eating raises the pH downstream, but the opposite happens where it matters: after a meal, the median pH in the duodenum falls to about 5.4 and stays there for hours, because acidic stomach contents are arriving faster than they can be neutralized. A coating engineered to open above 6.0, or above 7.0, is being asked to dissolve in a place that is temporarily too acidic for it. Taking a coated product with a large meal can push its release much later than intended.

Not everyone has an acidic stomach. In a study of 79 healthy older adults, about 11 percent had a resting stomach pH above 5, which is high enough to start dissolving most enteric films before they ever leave the stomach. The same thing happens pharmacologically: when people took omeprazole alongside an enteric-coated salicylate, absorption sped up measurably, consistent with the coating giving way early, while plain uncoated aspirin behaved no differently. If you take an acid reducer, your coated supplement is not necessarily doing what the box says.

These are not hypotheticals. In one imaging study of tablets coated for release far down the gut, one of the three coatings tested failed to disintegrate at all in three of eight volunteers, while the other two performed far better. And work comparing test conditions found that coated tablets dissolve markedly more slowly in fluid resembling real intestinal contents than in the standard laboratory buffers, meaning the official test is more forgiving than your actual gut. A product can pass and still underperform in a person. None of that makes coating useless. It means the sensible expectation is a shift in where the dose lands, not a precision drop.

Where it genuinely earns its price

Start with the case that settles the principle. Pancreatic enzymes, given to people whose pancreas no longer makes enough of its own, are destroyed by acid. Be clear about what those are, though: in the US every oral pancreatic enzyme product is a prescription drug, and the condition is diagnosed by a clinician rather than guessed at. Nothing here is a reason to buy an over-the-counter enzyme for suspected poor digestion. A classic intubation study measured what actually arrived downstream from uncoated pancreatin tablets and found only about eight percent of the swallowed lipase activity made it to the upper small intestine. That is the cleanest demonstration you will find that acid protection is not a marketing idea. Modern products solve it with enteric-coated microspheres small enough to leave the stomach alongside the food, and they work: pooled across trials, fat absorption rises from the low sixties to the low eighties as a percentage.

Here is the calibration a formulator owes you, though. That same meta-analysis found enteric coating showed a trend toward, not a proof of, superiority over uncoated enzyme, largely because only three small, heterogeneous studies compared the two head to head, which left the difference short of statistical significance rather than disproved. The coating is one solution to the acid problem, not a magic property.

Peppermint oil for irritable bowel syndrome is the second clean case, and the reason is unusual. Peppermint released in the stomach relaxes the valve at the bottom of the esophagus, which is exactly how you give someone heartburn. A 1969 study documented that effect directly. So the coating is meant to do double duty: keep the oil out of the stomach, where it would trigger that relaxation, and release the menthol further down where the antispasmodic action is wanted. That is the design rationale rather than a tested result. No trial has pitted a coated capsule against an uncoated one for reflux, and heartburn still turns up as a side effect in trials of coated capsules. Meta-analyses report meaningful benefit over placebo, and every one of those trials used a coated or delayed-release capsule. The American College of Gastroenterology suggests peppermint for IBS, though it is careful to call the recommendation conditional and the evidence low quality.

And the honest footnote, which most pages omit: the largest and most rigorous peppermint trial missed both of its primary endpoints. More interesting still, that trial tested two coatings, and the version engineered to release further along, in the ileum and colon, did no better than the one releasing in the small intestine. More targeting is not automatically better targeting.

The remaining genuine cases follow the same two rules. Omeprazole and its relatives are acid-labile drugs, which is why every oral version is delayed release, and the one immediate-release product drops the coating only by adding bicarbonate to neutralize the acid instead. Mesalamine and ileal-release budesonide exist to put a drug in a specific stretch of bowel, and with budesonide the coating buys a better safety profile rather than more potency. On the supplement shelf, the same logic legitimately covers acid-sensitive enzymes: this is why we treated delivery as a real buying criterion in our guide to DAO supplements. The same targeting logic is why butyrate is sold in coated and encapsulated forms, though the clinical evidence there is still thin.

Where the coating is mostly a story

Aspirin is the headline, and it is worth understanding properly because the belief is so widespread. The intuition is that a coated tablet cannot irritate the stomach lining, so it must be gentler. Coated aspirin genuinely does reduce the minor surface damage you can see through an endoscope. But that surrogate has never turned into fewer serious bleeds, because serious aspirin bleeding is mostly driven by the drug's systemic effect on platelets and prostaglandins, not by the tablet resting against the stomach wall. A large case-control study put the relative risk of major upper gastrointestinal bleeding at 2.6 for plain aspirin and 2.7 for enteric-coated. The US Preventive Services Task Force has stated it plainly: there is no evidence that enteric-coated or buffered formulations reduce the risk for serious gastrointestinal bleeding.

Meanwhile the coating extracts a cost. In a study of 400 healthy volunteers, a single coated 325 mg dose produced apparent aspirin resistance in up to 49 percent of people, against zero percent for immediate-release, and no true pharmacological resistance was found in anyone. The coating was not defeating the drug, it was delaying and reducing its absorption enough to look like failure. A separate study in people with type 2 diabetes found non-response in 52.8 percent on coated aspirin versus 15.8 percent on plain.

Two findings cut the other way and belong here. A small prospective study of 42 people found no difference in non-responsiveness between formulations, though it was almost certainly too small to detect one. And the largest comparison to date, a post hoc analysis of more than 10,000 patients inside a trial that randomized aspirin dose rather than coating, found neither better outcomes nor less bleeding with coating; its confidence interval for bleeding was wide enough that the authors said a reduction could not be excluded. Participants were grouped by the formulation they already reported taking rather than assigned to one, so the authors say it has to be read as observational. The fair summary is that the absorption penalty is real and does not reliably disappear with repeat dosing, since more than half the diabetes group were still non-responders after three daily doses, but it has not translated into worse clinical outcomes, and the safety benefit people are buying has never been demonstrated.

Fish oil is a gentler myth. Omega-3 absorption is not limited by stomach acid, so there is no mechanism by which a coating would improve it, and a head-to-head crossover confirmed that coated softgels offered no advantage over ordinary ones. The real pitch is fewer fishy repeats, which is plausible, but a search of the published literature for delayed-release omega-3 and burping returns nothing at all. Independent testers have also found coated fish oil releasing early, which defeats the purpose entirely. If repeat bothers you, treat it as a comfort question and see our fish oil guide for options.

Probiotics are the most oversold. Coating and microencapsulation do increase how many organisms survive the stomach, and that is measurable. But the endpoint in those studies is bacterial counts in stool, not whether anyone felt better, and no trial has shown that a coated product beats an uncoated one on a clinical outcome. The strains with the strongest evidence in the world built it in uncoated form. Cheaper levers do similar work: a little metabolizable sugar improved survival of one heavily studied strain in simulated gastric juice by orders of magnitude, taking the capsule with a meal protects the organisms well, and a manufacturer can simply add more. For which strains actually have evidence, see our probiotic guide.

Systemic enzymes such as serrapeptase and nattokinase are the weakest case, and the coating argument contains its own refutation. An enteric film opens in the duodenum, which is precisely where the pancreas delivers trypsin and chymotrypsin, the enzymes whose job is to dismantle proteins. Coating a protein to protect it from the stomach hands it to a different set of proteases instead, and a large hydrophilic protein still has to cross the intestinal wall intact to do anything systemic. That is reasoning rather than a trial, and it is worth labeling as such, but the clinical record is not kind either: a systematic review concluded the evidence for serrapeptase is insufficient to support its use, and the largest long-term nattokinase trial found no effect on any coagulation or vascular measure. Both may affect clotting, so anyone on blood thinners or heading for surgery should raise them with a clinician.

When a coating actively costs you

Some nutrients are absorbed in a specific window near the top of the small intestine, and a coating engineered to sail past that window is not neutral, it is a downgrade.

Iron is the clear case, and here the evidence is direct. In a crossover study of healthy volunteers comparing five ferrous sulfate preparations, the enteric-coated versions produced serum iron curves under 30 percent of what the plain oral solution achieved. Iron is taken up in the duodenum and upper jejunum, so a coating that opens later skips the very stretch that does the work. Clinicians have advised against coated and slow-release iron for treating deficiency for decades, and this is why.

Two related cases deserve a more careful label. Folate is carried across the gut wall by a transporter that works best in the slightly acidic layer right at the surface of the upper intestine, which makes bypassing that region theoretically unhelpful. Calcium carbonate needs stomach acid to dissolve at all: in people who make no acid, absorption from carbonate was roughly a tenth of that from citrate, though taking it with food normalized things. In both cases that is mechanism, not evidence. No one has run a head-to-head trial of coated versus uncoated folate or calcium, and this guide is not going to imply otherwise. For calcium the practical fix is food, not a coating.

The quick answer, by product

If you want one table to take shopping, this is it.

Verdicts reflect what a coating can accomplish for that category, not the merits of any individual brand. Drug examples are included because they carry the clearest published evidence about coating behavior; nothing here is advice about a prescription.

How to tell a real one

Now the uncomfortable part. In the United States, enteric coated on a supplement label is a description of intent, not a verified performance category. FDA's manufacturing rule for supplements, 21 CFR Part 111, does not require a company to set specifications for disintegration, dissolution, or bioavailability at all. The agency says so directly in its own compliance guide. So a firm can print the words without ever running the test, and without disclosing the result if it did.

That is not a reason for panic, and it is worth being careful here, because this fact gets weaponized to sell premium capsules. Independent testing finds real failures. In a market survey of vitamin and mineral products, 21 of 39 tablets did not disintegrate within 20 minutes on a deliberately harsh screen. Retested under the gentler official conditions for supplements a minority still failed, while every capsule passed. Three products in that survey were sold as time released and did not break down within the test window, but that is what an extended-release tablet is designed to do rather than a defect. Pulling the other way, a US Department of Agriculture analysis of adult multivitamins found roughly nine in ten disintegrated properly. Both numbers are true. Failures sit with tablets rather than capsules, but coating is not the tell: that same USDA analysis found coated tablets failed about as often as uncoated ones, and no single feature predicted which products would fail. A real minority problem, then, not the epidemic the marketing implies.

So here is the checkable test, and it takes about ten seconds:

• Read the other ingredients for a named polymer. Cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate, methacrylic acid copolymer or Eudragit, polyvinyl acetate phthalate, or shellac. A product claiming an enteric coat while naming none of these is making a claim you cannot check.
• Treat proprietary coating as a non-answer. There is no proprietary chemistry here worth hiding; the polymer list is public and boring.
• Look for a third-party mark such as USP Verified or NSF. These are the only widely available signals that the finished dosage form passed an independent performance test. Both are voluntary, paid, and rare, so their absence proves nothing, and neither guarantees where the product opens in a real person.
• Ask whether the payload needs it at all. If the answer is no, a coating is a reason to pay less attention to that product, not more.

Delivery is one axis of a supplement's quality; how much you absorb and which format suits you are others. We cover those in our guides to bioavailability and capsules versus gummies versus powders.

Frequently asked questions

What does enteric coated actually mean?

It means the tablet or capsule is wrapped in a polymer film that stays intact in acid and dissolves once the pH rises. Your stomach sits somewhere around pH 1.5 to 3.5, while the small intestine is closer to neutral, so a film engineered to open above roughly pH 5.5 will hold together in the stomach and let go further down. Delayed release is the broader regulatory term for that behavior. It is worth knowing that delayed release and extended or timed release are not the same thing: delayed release holds everything back and then lets it go at once, while extended release drips the dose out gradually over hours.

Does enteric-coated aspirin protect my stomach?

The evidence says no, at least not in the way people assume. Coated aspirin does reduce the small surface irritation you can see through an endoscope, but that has never translated into fewer serious bleeds. A large case-control study found essentially the same risk of major upper gastrointestinal bleeding for plain and enteric-coated aspirin, and the US Preventive Services Task Force stated plainly that there is no evidence enteric-coated or buffered formulations reduce the risk for serious gastrointestinal bleeding. Serious aspirin bleeding is driven by the drug acting throughout the body, not by the tablet touching the stomach wall. Do not change or stop aspirin your doctor prescribed on the strength of an article; raise it with them.

Do probiotics need an enteric coating?

Usually not, and the pitch oversells it. Coating and microencapsulation do measurably improve how many bacteria survive the stomach, but the endpoint in those studies is bacterial counts rather than whether anyone felt better, and no trial has shown a coated product beats an uncoated one on a clinical outcome. The most studied probiotic strains in the world earned their evidence in uncoated form. Cheaper things work about as well: taking the capsule with a meal protects the bacteria, a little metabolizable sugar dramatically improves survival in acid, and manufacturers can simply put more organisms in.

Does enteric-coated fish oil stop fishy burps?

It might, but nobody has actually published a trial showing it. A search of the medical literature for delayed-release omega-3 and burping or aftertaste returns nothing, so the claim rests on mechanism rather than evidence. What we do know is that the coating does not improve absorption: a head-to-head crossover found enteric-coated softgels gave no advantage over ordinary ones. Independent testers have also reported coated fish oil capsules releasing their oil too early, which removes the only benefit you were paying for. If repeat is your problem, it is a tolerability question, not an absorption one.

Can a coated pill really pass through you undigested?

It can happen, but it is rarer than the marketing suggests and it is worth being accurate about. An independent survey of vitamin and mineral products found real failures: 21 of 39 tablets did not break down within 20 minutes on a harsh screen. Retested under the gentler official conditions for supplements a minority still failed, while every capsule passed. Three products there were sold as time released and did not break down in the window, but slow erosion is what those are designed to do. Pulling the other way, a US Department of Agriculture analysis of adult multivitamins found roughly nine in ten disintegrated properly, and could not predict which would fail: coated tablets failed about as often as uncoated ones. So: a real minority problem that sits with tablets rather than capsules, not the epidemic sometimes used to sell premium capsules.

Is delayed release the same as time release?

No, and the labels get used loosely. Delayed release means nothing comes out until a trigger is met, almost always a rise in pH as the product leaves the stomach. Extended, sustained, or timed release means the dose is let out slowly over a period of hours, usually starting right away. They solve different problems: delayed release is about where the dose lands, extended release is about how fast it arrives. A product can be both, and some are, but a bottle that uses the terms interchangeably is not a great sign.

Does taking an acid reducer change how a coated supplement works?

It can, and it is rarely mentioned. An enteric film is designed to survive an acidic stomach, so if your stomach is not very acidic the film can begin dissolving early, releasing the contents in roughly the place the coating existed to avoid. That is not just theoretical: people given omeprazole alongside an enteric-coated salicylate absorbed it faster, consistent with the coating giving way sooner, while plain uncoated aspirin was unaffected. Age matters too, since a minority of healthy older adults have a resting stomach pH high enough to start the process. If you take a proton pump inhibitor or another acid reducer regularly, treat a delayed-release claim as less reliable, and mention it to your pharmacist if the product actually matters.

How can I tell whether a coating is real?

Read the other ingredients. A genuine enteric film uses one of a short list of pH-threshold polymers: cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate, methacrylic acid copolymer (often sold as Eudragit), polyvinyl acetate phthalate, or shellac. If the label says enteric coated but names none of those, or hides behind a proprietary coating, the claim is unverifiable. Beyond that, a third-party mark such as USP Verified or NSF is the only routinely available sign that the finished dosage form was actually tested for whether it breaks down properly, because those programs include performance testing. Both are voluntary and rare, so their absence is not proof of a bad product.

The bottom line

Ask one question of any coated product: what problem is this solving? If the active is destroyed by stomach acid, or it has to act somewhere specific further down, the coating is load-bearing and worth paying for. Pancreatic enzymes, peppermint oil for IBS, acid-labile drugs, and acid-sensitive enzymes all clear that bar. If neither is true, you are buying reassurance. And for a few things, iron most clearly, the coating moves the dose past the window where it would have been absorbed, which makes it worse than the cheap version. When you do want delayed release, verify it the boring way, by finding the polymer on the label, and remember that even a well-made coating is an aim rather than a guarantee.